Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS)

Int J Lab Hematol. 2007 Oct;29(5):395-7. doi: 10.1111/j.1365-2257.2006.00860.x.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Bone Density Conservation Agents / therapeutic use*
  • Diphosphonates / therapeutic use*
  • Humans
  • Imidazoles / therapeutic use*
  • Middle Aged
  • Multiple Myeloma / complications*
  • Multiple Myeloma / drug therapy
  • Osteoporosis / drug therapy*
  • Osteoporosis / etiology
  • Paraproteinemias / complications*
  • Paraproteinemias / drug therapy
  • Zoledronic Acid

Substances

  • Bone Density Conservation Agents
  • Diphosphonates
  • Imidazoles
  • Zoledronic Acid